Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro-anabolic mediators.

Aging cell - 1 Jan 2025

Maurer Svenja, Kirsch Valeria, Ruths Leonie, Brenner Rolf E, Riegger Jana

Abstract excerpt

Cellular senescence is associated with various age-related disorders and is assumed to play a major role in the pathogenesis of osteoarthritis (OA). Based on this, we tested a senolytic combination therapy using Dasatinib (D) and Quercetin (Q) on aged isolated human articular chondrocytes (hACs), as well as in OA-affected cartilage tissue (OARSI grade 1-2). Stimulation with D + Q selectively eliminated senescent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cartilage, Articular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cellular Senescence

Share to Chondrocytes

Share to Chondrogenesis

Share to Dasatinib

Share to Osteoarthritis

Share to Quercetin

Source

Open in PubMed Open full text

Identifiers

PMID: 39402753
DOI: 10.1111/acel.14361
PMCID: PMC11995296

Genes

ACAN
COL2A1
CXCL1
FGF18
IGF1
IL6
SOX9
TGFB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro-anabolic mediators.PMID 39402753Read ↗

Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by promoting the release of pro-anabolic mediatorsSemantic proximity Read ↗

Combined senolytics induce varied phenotypic and functional responses on senescent phenotypes of mesenchymal stromal cell populations.Semantic proximity Read ↗

The role of chondrocyte senescence in osteoarthritis pathogenesis and therapeutic implicationsSemantic proximity Read ↗

Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice.Semantic proximity Read ↗

Cellular senescence in osteoarthritis and anti-aging strategies.Semantic proximity Read ↗

<i>In vitro</i> and <i>in vivo</i> effects of zoledronate on senescence and senescence-associated secretory phenotype markersSemantic proximity Read ↗

Eliminating senescent chondrogenic progenitor cells enhances chondrogenesis under intermittent hydrostatic pressure for the treatment of OASemantic proximity Read ↗

Targeting senescent cells by dasatinib and quercetin ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration.Semantic proximity Read ↗

Targeting cellular senescence as a novel treatment for osteoarthritis.Semantic proximity Read ↗

Fisetin suppresses chondrocyte senescence and attenuates osteoarthritis progression by targeting SIRT6Semantic proximity Read ↗

ESC-sEVs alleviate non-early-stage osteoarthritis progression by rejuvenating senescent chondrocytes via FOXO1A-autophagy axis but not inducing apoptosisSemantic proximity Read ↗

Mechanisms and therapeutic implications of cellular senescence in osteoarthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.